**10x Genomics Reports 5% Revenue Increase in 2025, Focuses on Strategic Growth**
10x Genomics, Inc., a life sciences technology company, announced a 5% increase in revenue for the fiscal year 2025, reaching $642.8 million compared to $610.8 million in 2024. The company reported a net loss of $43.5 million for 2025, a significant improvement from the $182.6 million net loss in the previous year. Instrument sales totaled 1,007 units in 2025, while consumable reactions reached 424,000. The company's product offerings are categorized into single cell and spatial portfolios, with the Chromium platform driving the single cell analysis and the Visium and Xenium platforms powering spatial analysis.
The company's strategic developments in 2025 included the acquisition of Scale Biosciences, Inc., which added QuantumScale Single Cell RNA and Single Cell Methylation kits to its single cell portfolio. 10x Genomics continues to focus on research and development to improve existing technologies and develop new solutions across its portfolios. The company estimates its total addressable market at over $21 billion annually and its serviceable addressable market at over $13 billion annually. As of December 31, 2025, the company had sold 8,046 instruments since launching its first product in mid-2015.
Operationally, 10x Genomics has expanded its commercial operations to over 50 countries, primarily selling directly in North America and certain regions of Europe. As of December 31, 2025, the company's commercial organization consisted of 473 full-time employees. The company also utilizes third-party distributors in certain regions of Asia, Europe, Oceania, North America, South America, the Middle East, and Africa. Sales to academic and government institutions represent the largest portion of direct sales revenue, with biopharmaceutical companies expected to contribute a growing proportion in the future.
Looking ahead, 10x Genomics plans to focus on improving the performance of existing technologies, developing new solutions for its portfolios, and enhancing instrument capabilities. The company also aims to develop combined software and workflows across multiple solutions and investigate new technologies. As of December 31, 2025, 10x Genomics employed 1,178 individuals, with 822 in the United States and 356 outside the United States. The company's success is dependent on its ability to obtain, maintain, enforce, and defend intellectual property rights, as well as navigate government regulations and data privacy laws.
About 10x Genomics, Inc.
10x Genomics, Inc. is a life sciences technology company dedicated to advancing human health through innovative biological analysis solutions. Its key products, including the Chromium, Visium, and Xenium platforms, enable high-resolution single-cell and spatial analysis. With a $21 billion addressable market, 10x targets academic, biopharmaceutical, and research institutions. The company emphasizes R&D and customer collaboration to drive product development, aiming to enhance biological understanding and discovery across various fields.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.